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Abstract: The 5’-untranslated region (5’UTR) of the HIV-1 RNA is an attractive target for 
engineered ribozymes due to its high sequence and structural conservation. This region 
encodes several conserved structural RNA domains essential in key processes of the viral 
replication and infection cycles. This paper reports the inhibitory effects of catalytic 
antisense RNAs composed of two inhibitory RNA domains: an engineered ribozyme 
targeting the 5’ UTR and a decoy or antisense domain of the dimerization initiation site 
(DIS). These chimeric molecules are able to cleave the HIV-1 5’UTR efficiently and 
prevent viral genome dimerization in vitro. Furthermore, catalytic antisense RNAs 
inhibited viral production up to 90% measured as p24 antigen levels in ex vivo assays. The 
use of chimeric RNA molecules targeting different domains represents an attractive 
antiviral strategy to be explored for the prevention of side effects from current drugs and of 
the rapid emergence of escape variants of HIV-1. 
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1. Introduction 
The human immunodeficiency virus (HIV-1) is the etiological agent of AIDS [1]. It primarily 
targets CD4+ cells like T cells and macrophages, leading to the suppression of their immune function. 
The quasi-species structure of the viral population and its high mutation rate enable the virus to rapidly 
evade the immune response and promote the appearance of variants resistant to therapeutic drugs. 
Current therapies are based on a combination of different viral protein inhibitors that achieve a high 
reduction of the viral load, allowing a partial restoration of the immune function. Patients must 
maintain an aggressive lifelong treatment which produces serious side effects, so there is a real need to 
pursue the development of new therapies. Besides carrying the genetic information the HIV genomic 
RNA contains several conserved structural domains which play essential roles in viral replication and 
infection cycles. These functional RNA domains exhibit the highest sequence and structural 
conservations of the viral genome, making them very attractive therapeutic targets. The direct targeting 
of the viral RNA genome to interfere with the function of genomic RNA domains is a strategy to be 
explored, with nucleic acids being strong candidates as specific inhibitors for the development of this 
potential therapeutic technology.   
The HIV is a lentivirus which contains two long directly repeated regions at both ends of the 
genome. The 5’-untranslated region (5’UTR) of primary RNA transcripts comprises several functional 
RNA domains involved in key processes of the viral cycle like the trans-activation of transcription, 
polyadenylation, reverse transcription, dimerization, splicing and packaging [2]. The HIV infective 
particles contain two non-covalently linked genomic RNA copies that are bound through their 5’ ends. 
The dimerization process is initiated at the dimerization initiation site (DIS) stem-loop domain. The 
DIS contains a palindrome sequence motif within the apical loop which is involved in the initial 
homodimerization interaction by a kissing-loop mechanism which is thought to progress to a more 
extended interaction [3]. It has been proposed that the availability of the DIS structure is controlled by 
a riboswitch which alternates between two main 5’UTR conformers termed branched multiple hairpins 
(BMH) and long distance interaction (LDI) forms [4]. The existence of one or other of the 
conformational structures may determine the switch between full-length viral RNA packaging and 
translation processes [5]. In silico studies based on biochemical data support the notion that the LDI is 
the most abundant conformer [6], while ex vivo structure probing assays indicate the prevalence of the 
BMH conformer, i.e. the dimerizing-competent form [7]. Both conformers have been visualized in 
native gel electrophoresis using mutants that disrupt the equilibrium between both conformers [4].  
The minimal catalytic domains of the natural hammerhead and hairpin ribozymes have been 
engineered to generate trans-cleaving catalytic RNAs (Figure 1A) [8-10], and their substrate sequence 
requirements have been defined [11-14]. The therapeutic potential of the hammerhead and the hairpin 
catalytic motives has been widely proven [15]. We have previously shown efficient HIV-1 RNA 
inhibition by using inhibitor RNAs based on either hairpin or hammerhead ribozymes [16,17]. 
We report here the characterization of a series of chimeric molecules composed of a trans-cleaving 
ribozyme, either a hairpin or a hammerhead, targeting two different sites within the HIV-5’UTR and 
an anti-DIS specific molecule, either a DIS sense molecule that may act as a decoy element and an 
antisense DIS molecule (Figure 1B). In vitro analysis demonstrated that both sense and antisense-DIS 
domains interfere with viral dimerization. The antiviral activity was evaluated by transfecting cells 
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with either pre-synthesized RNA molecules or plasmid DNAs encoding the chimeric  
inhibitor RNAs.  
Figure 1. (a) Schematic representation of the catalytic RNAs. Self-cleaving hammerhead 
(top left) and hairpin (top right) ribozymes are represented. Engineered trans-cleaving 
ribozymes are represented at the bottom. The thinner line represents substrate RNA and the 
arrows indicate the cleavage points. (b) The wild type complete DIS domain of NL4.3 
HIV-1 strain is shown on the left while the two inhibitory moieties used in this study, DIS 
sense and antisense (αDIS), are shown on the right. (c) Ribozyme sequence requirements 
and target sites 113 and 159 are indicated. Vertical lines represent the cleavage site. 
Nucleotide code: N stands for A, U, G or C; B stands for C, G or U; H stands for A, C or 
U; Y stands for C or U; and R stands for A or G. (d) Schematic representation of the 
catalytic chimera RNA series used in the in vitro experiments. The ribozyme domain 
coding sequences were flanked by EcoRI and BglII sites, while the decoy or antisense DIS 
domain were flanked by BglII and BamHI sites. (e) Sequences of all combinations of 
chimeric RNAs used in this study. Grey boxes indicate the substrate recognition arms of 
the ribozyme domains. (f) Schematic representation of the chimeras used in the ex vivo 
inhibition assays, inhibitor RNAs are flanked by U6 snRNA end hairpin loops. 
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2. Results and Discussion 
2.1. In vitro HIV-1 RNA cleavage by anti-HIV-1 catalytic RNAs 
Hairpin (HP) and hammerhead (HH) ribozymes were designed to target sequences 107-120 and 
153-166 of the NL4.3 HIV-1 strain, which we had previously shown as being sequences accessible to 
both kinds of ribozyme [18]. Engineered HH ribozymes cleave at the 3’ side of nucleotides 114 and 
160, while HP ribozymes cleave at the 3’ side of nucleotides 111 and 157 (Figure 1C). The sequence 
of these ribozymes and their targets is represented in Figure 1 and we will refer to them as HH113 and 
HP113 for those targeting the 107-120 region (they cleave surrounding position 113) and HH159 and 
HP159 for those targeting the 153-166 region (they cleave surrounding position 159). 
The DIS region is a 34 nt-long RNA domain folded into a stem-loop structure that expands from 
nucleotide position 244 to 278 in the NL4.3 HIV-1 strain. A molecule containing the 23 most apical 
nucleotides of the DIS stem-loop, positions 249 to 271, was used as the decoy domain (DIS). A 
molecule having the complementary sequence of the same 23 nt was used as the antisense domain 
(αDIS; Figure 1B). The decoy or the antisense molecules were covalently linked to the 3’ end of 
HH113, HH159, HP113 and HP159 ribozymes to yield a series of potential HIV inhibitors named HH 
or HP-DIS or αDIS when carrying the sense or the antisense sequence, respectively (Figure 1C). In 
addition, the stem-loop flanking domains of the U6 snRNA were added to either end of the inhibitor 
RNA molecule to make them of the same structure as those to be assayed in the culture cells. For anti-
viral activity assays, RNA chimeras were cloned into a mammalian pcDNA3-derived plasmid 
containing a U6 snRNA promoter cassette which directs the synthesis of inhibitor RNAs [19]. 
Transcription from this promoter yields RNA products flanked by the first and the last stem-loops of 
the U6 snRNA (Figure 1E). 
In vitro cleavage activity of each chimera RNA was assayed and compared to that of the 
corresponding trans-cleaving ribozyme lacking any additional domain (Figures 1D and E). An in vitro 
transcribed HIV-1 5’UTR molecule containing the first 308 nt was used as the substrate of the 
reaction. Cleavage reactions were performed at 37 ºC in a cleavage buffer and the reaction progression 
was monitored at different times (Table 1 and Figure 2). All RNAs follow a hyperbolic pattern of 
cleavage percentage during the reaction time, with a 100% cleavage expected from all of them with a 
lowest r2 coefficient of 0.8824. We defined the T0.5 coefficient as the time, in minutes, that was 
necessary to reach 50% of the cleaved substrate. The hairpin ribozymes HP113 and HP159 had lower 
T0.5 values, 16.25 ± 2.17 and 19.47 ± 6.05 min, respectively, compared to their hammerhead 
counterparts, HH113 and HH159 with 22.89 ± 9.89 and 118.9 ± 39.54 min, respectively (Table 1). 
The addition of either sense or antisense DIS domains resulted in a slight modification of the T0.5 
value with respect to the one of the ribozyme alone (Table 1). The highest improvement was recorded 
for HH159 with the addition of the αDIS domain, which resulted in a nearly two-fold reduction of the 
T0.5. On the opposite side, the addition of the DIS domain to the HP113 ribozyme produced a two-fold 
increase of the T0.5. 
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Figure 2. Cleavage reactions of 5’UTR by ribozymes and chimeric RNA molecules. Each 
gel autoradiograph shows a representative cleavage reaction time course of a specific 
ribozyme and its respective DIS and αDIS derived chimeras: (a) HH113, (b) HH159, (c) 
HP113 and (d) HP159. Each experiment was performed in triplicate and the cleavage 
percentage was obtained by quantification of the cleavage products. Curves were fitted 
with maximum sqr(R) coefficients. 
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Table 1. In vitro cleavage reactions of the HIV-5’ UTR by catalytic RNAs. (a) T0.5 values 
were normalized to the one of the corresponding ribozyme. (b) Regression curves were fixed 
to a maximum cleavage value of 100%. 
RNA Maximum cleavage (%) T0.5 (min) Relative T0.5
(a) sqr(R) (b) 
HH113 100 ± 14.23 22.89 ± 9.88 1 0.8824 
HH113DIS 100 ± 10.21 24.92 ± 7.43 1.08 0.9417 
HH113αDIS 100 ± 7.99 25.4 ± 5.88 1.11 0.9667 
HP113 100 ± 3.78 16.25 ± 2.17 1 0.9863 
HP113DIS 100 ± 6.15 32.34 ± 5.17 1.98 0.9823 
HP113αDIS 100 ± 5.67 20.99 ± 3.75 1.28 0.9746 
HH159 100 ± 21.26 118.9 ± 39.54 1 0.9764 
HH159DIS 100 ± 10.94 75.48 ± 15.15 0.63 0.986 
HH159αDIS 100 ± 11.84 62.25 ± 14.57 0.52 0.9783 
HP159 100 ± 9.53 19.47 ± 6.05 1 0.9369 
HP159DIS 100 ± 14 24.44 ± 10.08 1.25 0.8942 
HP159αDIS 100 ± 9.1 16.61 ± 5.28 0.85 0.9322 
We previously reported that the addition of a TAR antisense domain (αTAR) to the same HP and 
HH ribozymes used in this work, resulted in an improvement of the cleavage activity [18]. The TAR 
RNA shares common features with natural antisense RNAs and this could explain why the αTAR-
TAR interaction was able to mimic the fast and stable interactions of natural antisense RNAs and their 
targets, thus explaining the reported improvement in catalytic activity [18,20,21]. Neither DIS nor 
αDIS domains conserved the features of natural antisense, which may explain the lack of cleavage 
activity enhancement. 
2.2. In vitro inhibition of the 5’UTR dimerization by catalytic RNAs 
The HIV-1 virion particles contain two genome RNA copies. The process by which two genome 
copies get non-covalently bond is called dimerization and it is initiated at the DIS domain located at 
the 5’-end of the genomic RNA [22]. The dimerization process can be reproduced in vitro in a high salt 
concentration and can be resolved by native gel electrophoresis [23]. 
To check whether the inhibitory chimera RNAs might interfere with the dimerization process, both 
molecules (inhibitory RNA and 5’UTR) were mixed together in H2O, using a 20-fold molar excess of 
non-radiolabelled inhibitory RNA. The dimerization reaction was started by the addition of a reaction 
buffer. The dimer fraction was detected as the molecular species showing a slower mobility in a native 
polyacrylamide gel electrophoresis. The RNA chimeras based on HH159 and HP159 clearly interfered 
with dimer formation whereas ribozymes HH159 and HP159 did not have any effect. These chimeras 
led to an almost complete suppression of the dimer in favour of the appearance of a new species which 
migrates between the dimer and the monomer. This new species might be a heterodimer formed 
between the inhibitory RNA and the 5’UTR, although we cannot rule out other possibilities (Figure 3). 
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Figure 3. Inhibition of 5’UTR dimerization in vitro by chimeric inhibitor RNAs derived 
from both hammerhead and hairpin ribozymes [A) and B), respectively). The 5’UTR 
dimerization was performed in the presence and absence of inhibitor RNAs. Dimerization 
reactions were carried out at 37 ºC for 20 min with 157 nmol of internally radiolabelled 
5’UTR RNA and a 20-fold excess of inhibitory RNA. The reactions were resolved in 4% 
polyacrylamide native gels. Line 1 in both gels represents non-dimer condition controls. 
Line 2 represents 5’ UTR dimerization in the absence of any RNA inhibitor. The shifted 
band within line 2 with respect to line 1 is considered as the dimer. 
 
 
Similarly, the HH113 and HP113 chimeras also suppressed dimer formation almost completely and 
yielded a new species, supposedly a heterodimer, which was detected between the dimer and the 
monomer. Surprisingly, ribozymes HP113 and HH113 induced the appearance of a new molecular 
species that migrates between the heterodimer and the 5’UTR-5’UTR homodimer and a second species 
that migrated faster in the gel. Interestingly, catalytic RNAs targeting position 113 were the only 
inhibitors able to cleave the substrate under dimerization conditions (data not shown). It is feasible that 
the new species detected might correspond to a partially or completely cleaved dimer, which would 
explain the disappearance of the dimer species in the presence of HH113 (Figure 3). Likewise, 113 
ribozymes interacting with 5’UTR cleavage region might switch the equilibrium towards the LDI 
conformer. It was previously reported that mutations in unrelated regions like TAR switch the 5’UTR 
isoform equilibrium towards one or the other of the conformers [24]. It is worth noting that the HH 
ribozymes used in this work maintained a perfect base pairing with the target sites within the 5’ UTR 
sequences. These target sequences completely met the HH defined consensus requirements. However, 
one mismatch existed between the binding arms and the target site for HP113, and two for HP159, 
which could affect HP159 cleavage efficiency under dimerizing conditions (Figure 1C). Furthermore, 
position 159 was predicted to be involved in a stem-loop structure in both BMH and LDI conformers 
while position 113 only appeared as single stranded in the BMH form, which could explain why 113 
ribozymes were able to cleave the target despite non-optimal conditions while 159 ribozymes were not.  
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2.3. Inhibition of HIV-1 ex vivo viral production by endogenously synthesized inhibitory RNAs 
A HEK293T cell system was used for assaying the effect of inhibitor RNAs on HIV viral 
production.  The HEK293T cells do not express the surface receptors required for HIV-1 infection; the 
virus can replicate in these cells but viral particles cannot infect them. Transfection with pro-viral 
DNA mimics the post-integration stage of the viral cycle and viral particles in the supernatant after 
transfection correspond to first generation virions. 
Figure 4. Ex vivo inhibition of HIV-1 viral production. The HEK293T cells were 
transfected with the pNL4.3 plasmid and an inhibitory RNA expressing vector at a molar 
ratio of 1:10 A) or with an in vitro synthesized RNA B). The bar graph represents the 
percentage of viral protein p24 levels in the supernatant 48 hours after transfection relative 
to the control. The inhibitory RNA is indicated below each bar. The empty pU6 vector and 
an RNA molecule consisting of both U6 snRNA flanking hairpins without any sequence in 
between were used as negative controls in A) and B), respectively. The results are the 
means of three independent experiments (** p < 0.01). 
 
 
Inhibitor RNAs were cloned in a pcDNA3-derived plasmid, pU6, in which both CMV promoter and 
BGH polyadenylation signals were substituted by those belonging to human U6 snRNA [16]. The pU6 
plasmid constructs encoding HH113DIS and HH159DIS RNAs were not obtained. The HEK293T 
cells were co-transfected with pNL4.3 and a pU6-inhibitor RNA. Intracellular expression of the pro-
viral DNA encoded in the pNL4-3 plasmid allowed the viral replication cycle. The pU6-construct 
series allowed endogenous production of the inhibitor RNAs to be tested. Viral production was 
determined as a measurement of the viral protein p24 in cellular supernatant two days after 
transfection. The HH113αDIS and HP159DIS RNAs reached extracellular protein p24 inhibition rates 
of 92.68 ± 1.31% and 83.64 ± 3.78%, respectively. The HP113αDIS and HH159αDIS RNAs reached 
inhibitions rates close to 50%, while HP159αDIS and HP113DIS had no significant effect (Figure 4A). 
It was previously reported that the expression of single ribozymes does not interfere with HIV-1 viral 
production under these conditions [16].  
2.4. Inhibition of HIV-1 viral production ex vivo by pre-synthesized inhibitory RNAs 
To further characterize the inhibitory efficiency of these RNAs, a similar experiment to the one 
described above was performed, but this time in vitro synthesized inhibitory RNAs were transfected. 
These RNAs were transcribed in vitro by T7 RNA polymerase from PCR templates obtained by 
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amplification from the pU6 constructs. The templates were designed to obtain RNAs containing both 
U6 snRNA flanking hairpins in order to be identical to those produced by the U6-driven expression 
cassettes (Figure 1F). As a control, an RNA consisting of the U6 snRNA flanking hairpins without any 
sequence in between was used. 
The HEK293T cells were co-transfected with pNL4.3 and inhibitory RNAs. Viral protein p24 levels 
in supernatant were measured 48 hours after transfection. Up to 80% inhibition was obtained with 
HH113αDIS RNA, a similar value to the one obtained when it was endogenously synthesized from the 
U6 construct derivative. However, no significant effect was observed for the other tested RNAs 
(Figure 4B). 
2.5. HIV-1 inhibition by catalytic RNAs is not explained by the interferon response 
Total RNA was extracted from HEK293T cells co-transfected with pU6 constructs and pNL4.3 at 
the moment of quantifying viral protein p24 in the supernatant. The RNA was reverse transcribed 
using random hexamers and cDNA as a template for PCR, using specific primer pairs for the GAPDH 
and ISG56 genes. The interferon stimulated gene 56 (ISG56) is a gene induced by double-stranded 
RNA and virus infection [25,26]. Basal expression levels are nearly undetectable. Semiquantitative 
RT-PCR was performed to detect ISG56 mRNA as reporter of interferon-signalling activation using 
the housekeeping GAPDH gene as the internal control (Figure 5). Poly I:C is a double-stranded RNA 
that quickly triggers the interferon response; it is used as a positive control of interferon response 
induction. Semi-quantitative RT-PCR from total RNA extracted from poly I:C transfected cells 
generated a detectable ISG56 amplification. On the contrary, RT-PCR from total RNA extracted from 
cells solely transfected with pNL4.3 did not yield any ISG56 amplification products (Figure 5).  
Figure 5. Assay of the interferon response. A representative photograph of an agarose gel 
visualized by ethidium bromide transluminescence is shown. Transfected DNAs are 
indicated on top of each lane. The NTP, control PCR reaction in the absence of any 
template. NRT, PCR reaction from total RNA without previous reverse transcription were 
checked for genomic DNA contamination. The poly I:C was a positive control of the 
interferon response. The amplicons are identified by the name of the gene on the left. Sizes 
of marker DNA fragments in bp are indicated on the right. 
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Amplification of the ISG56 gene was not observed in any RT-PCR from total RNA extracted from 
cells co-transfected with pNL4.3 and any of the following pU6 construct derivatives: empty vector, 
HP113DIS, HH113αDIS, HP113αDIS or HP159αDIS (Figure 5). Only interferon signalling was 
slightly induced by the pU6 HH159αDIS construct and to a lower extent by pU6 HP159DIS (Figure 
5). These results indicate that the highest viral inhibition recorded by pU6 HH113αDIS and pU6 
HP159DIS cannot be explained by the induction of interferon-signalling, suggesting that the observed 
inhibition corresponded mainly to specific inhibition resulting from the direct action of the inhibitor 
RNAs on viral RNA. Nor was the viral inhibition produced by HP113αDIS due to the induction of 
interferon signalling. 
2.6. Relationship between the HIV-1 RNA dimerization process and the structural conformation of the 
5’UTR 
The monomeric conformers LDI and BMH could not be resolved under the dimerization conditions 
tested (Figure 6A, lines 1 and 2 from the left of each gel). However, the internally labelled 5’ UTR in 
the absence of any reaction buffer was resolved in a native polyacrylamide gel using 0.25X TBE in the 
gel and the running buffer, and a new conformer showing a slightly retarded mobility was observed. 
(Figure 6A, first line). We associated the fast and slow migrating monomers to LDI and BMH forms, 
respectively. Ionic strength stabilized the highly imperfect LDI helices, while conserved BMH hairpins 
were favoured in their absence. The monomer detected under dimerization conditions might 
correspond to the LDI conformer (fast migration). A dimerization reaction time course was performed 
to study the progression of the reaction (Figure 6A, odd lines). The BMH form extinguished between 
10 and 30 min after dimerization started, while maximum dimerization was reached at no later than  
30 min (Figure 6A). Only a minor percentage of the 5’UTR RNA population formed a dimer. This 
suggests that once the salt is added to the mix, the 5’UTR BMH conformer quickly switches to the LDI 
conformer, and only a minor proportion of molecules progress to dimer formation. This might explain 
why these inhibitor chimera RNAs with DIS or αDIS did not behave like αTAR ones, increasing the 
percentage of cleaved molecules in vitro. The TAR is present within both LDI and BMH conformers, 
while the DIS structure is only present in a very limited percentage of the 5’UTR molecules.  
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Figure 6. Involvement of the different 5’UTR conformers in the RNA dimerization 
process. (A) Autoradiogram of a polyacrylamide gel electrophoresis of a 5’ UTR 
dimerization reaction time course. Dimerization reactions were performed as described in 
the experimental section. Different molecular species are identified at the left side of the 
gel. (B) The thermodynamic relationship between 5’UTR RNA isoforms. Line 1 (water): 
5’UTR was denatured and renatured in water. Line 2 (–DIS decoy): 5’UTR was denatured 
and renatured in water, and incubated for 40 min at 37 ºC in 1X dimer buffer. Line 3 (+DIS 
decoy): the same procedure as line 2, but a 60-fold molar excess of unlabelled DIS decoy 
was added at time 0. Line 4 (+DIS decoy after 40 min): the same procedure as line 2 but a 
60-fold molar excess of unlabelled DIS decoy was added after 40 min incubation in 
dimerization conditions; the reactions were followed for another additional 40 min at  
37 ºC. Line 5 (+DIS decoy): the same procedure as line 2, but the DIS decoy was internally 
radiolabelled and 5’UTR unlabelled. Different molecular species are identified by a 
schematic representation depicted on the right side of the gel. 
 
 
To further characterize the anti-HIV dimerization effect of the inhibitory RNAs, a DIS decoy RNA 
was used as a competitor. The DIS decoy might stabilize BMH within a heterodimer and could be a 
tool for the identification of different isoforms and for understanding their equilibrium relationships. 
Dimerization reactions were performed in the presence of a 60-fold molar excess of a cold 23 nt-long 
DIS decoy, which was added to the mix just before the reaction began. The DIS decoy completely 
abolished dimer formation, while a new RNA complex appeared which migrated slightly slower than 
the BMH monomers (Figure 6A, even lines). The same experiment was performed using cold 5’UTR 
and a radiolabelled DIS RNA decoy, and revealed that the decoy is only present in the new slow 
migrating complex, so this new molecular species must be an 5’UTR-DIS heterodimer (Figure 6B, 
fourth line). These results suggest that the DIS decoy sequesters the dimerization-competent BMH 
conformer from natural dimerization. However, no competition was observed when the DIS decoy was 
added 40 min after the reaction started (Figure 6B). This indicates that the BMH homodimer is stable 
enough and a dynamic equilibrium does not exist between the dimer and the LDI monomer via the 
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ephemeral BMH. This phenomenon explains why the 5’UTR was able to dimerize by the BMH-
dependent DIS domain, despite the large thermodynamic displacement toward the LDI form. In any 
case, the chaperone activity of the nucleocapsid protein could probably displace the equilibrium 
towards the dimer formation and explain the BMH conformer predominance obtained by ex vivo 
probing assays [3]. 
3. Experimental 
3.1. RNA preparation and vector construction  
Inhibitor RNAs were obtained by in vitro transcription from appropriate DNA templates using 
bacteriophage T7 RNA polymerase. The DNA templates were generated from pG3HH and pG3HP 
anti-LTR HIV-1 plasmid series as described by Puerta-Fernández and co-workers [18] by replacing the 
antisense TAR coding sequence by either a DIS or an antisense DIS (αDIS) coding sequence.  Briefly, 
DIS and αDIS coding sequences were obtained by annealing DISf 
(5’GATCTCTTGCTGAAGCGCGCACGGCAAGG3’) and DISr (5’GATCCCTTGCCGTGCGCGCT 
TCAGCAAGA3’) oligonucleotides or αDISf (5’GATCTCTTGCCGTGCGCGCTTCAGCAAGG3’) 
and αDISr (5’GATCCCTTGCTGAAGCGCGCACGGCAAGA3’) oligonucleotides, respectively. The 
oligonucleotides were 5’ end phosphorylated by T4 polynucleotide kinase (Roche, Switzerland) before 
annealing, following the manufacturer’s instructions. Each pG3HH and pG3HP construct was digested 
with BglII and BamHI restriction enzymes to eliminate the antisense TAR domain coding sequence 
and ligated with the DIS inserts, yielding the new pG3HH and pG3HP series encoding anti-DIS 
sequences. In vitro transcription was performed as previously described [18] from BglII or BamHI 
linearized pG3HH and pG3HP plasmid templates to synthesize ribozymes or inhibitor chimera  
RNAs, respectively. 
Ex vivo expressing plasmid constructs were generated from the pU6-Rzs plasmid series as described 
previously [16]. Inhibitor RNA coding sequences were obtained by PCR amplification using the 
constructs described above as templates, and the oligonucleotides 5’KpnIpK 
(5’GACTCGGTACCGGGCGAATT3’) and 3’ApaIpK (5’TCTAGAGGGCCCCCTTGC3’). 
Amplicons were digested with KpnI and ApaI and cloned in the KpnI and ApaI unique restriction sites 
within the U6 promoter cassette of the pU6-Rzs plasmid series.  
Pre-synthesized RNAs for ex vivo HIV-1 inhibition assays were generated by in vitro transcription 
with T7 RNA polymerase from PCR amplicons. Templates were generated from the pU6 constructs 
using 5’T7U6 (5’TAATACGACTCACTATAGGGGTGCTCGCTTCGGCAGCACAT3’) and 
3’ApaIU6 (5’AGCGGGCCCAAAAAGCGGACCGAAGTCCGC3’) oligonucleotides which contained 
the T7 RNA polymerase promoter at the 5’ end. Transcription from these templates yielded chimera 
RNAs containing U6 snRNA flanking hairpins at both ends, as they would be generated by  
ex vivo transcription.  
The 5’UTR RNA was transcribed in vitro by T7 RNA polymerase from a PCR template obtained 
from the pNL43 plasmid (GeneBank no. AF324493) with primers 5’T7NL43 (5’TAATACGACTCA 
CTATAGGGTCTCTCTGGTTAC3’) and 3’T7NL43 (5’AATTTTTGGCGTA CTCACCAGT3’). The 
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amplicon incorporated the T7 RNA polymerase promoter at the 5’-end of HIV-1 genomic region from 
the +1 to +308 nucleotide coding sequence. 
3.2. In vitro cleavage assays 
The cleavage reactions were performed in a 10 µL final volume in the presence of 0.2 nmol of 
internally radiolabelled 5’UTR RNA and 20 nmol of non-radiolabelled catalytic inhibitor RNAs. The 
RNA mix was denatured (10 min 65 ºC) and renatured (10 min 37 ºC) in H2O and the reaction was 
initiated by the addition of 2 µL of 5X cleavage buffer (1X: Tris-HCl 50 mM pH 7.5; MgCl2 10 mM) 
and incubated at 37 ºC. Aliquots were taken at different times (10, 30, 60 and 90 min) and the reaction 
stopped by adding an equal volume of 2X denaturing loading buffer (2X: deionized formamide 94% 
v/v; xylene cyanol 0.025% p/v; bromophenol blue 0.025% p/v; EDTA 17 mM). The results were 
resolved in 8% denaturing polyacrylamide gels in 1X TBE using 0.5X TBE as the running buffer.  
3.3. In vitro dimerization assays 
Dimerization competition reactions were performed in a final volume of 10 µL. Internally 
radiolabelled 5’UTR RNA (157 nmol) was mixed with non-radiolabelled inhibitory RNA (3.14 pmol) 
in 8 µL H2O. The RNA mix was denatured (10 min 65 ºC) and renatured (10 min 37 ºC) and the 
reactions were initiated by the addition of 2 µL of 5X dimerization buffer (1X: sodium cacodylate  
50 mM pH 7.5; KCl 0.3 M; MgCl2 5 mM). The reactions were performed for 20 min at 37 ºC and then 
stopped by the addition of a same volume of 2X native gel loading buffer (2X: Tris-acetate 20 mM; 
Mg acetate 10 mM; NaCl 0.1M; glycerol 30% v/v; xylene cyanol 0.4% p/v; bromophenol blue  
0.4% p/v; tRNA 4% p/v). The reaction products were resolved by 4% native polyacrylamide gel 
electrophoresis in 1X TBE using 1X TBE as the running buffer. Electrophoresis was performed at 4 ºC 
and no more than 15 mA per gel. Monomerization control was performed by the addition of 5X 
monomerization buffer (1X: sodium cacodylate 50 mM pH7.5; KCl 0.3 M; MgCl2 0.1 mM). For 
detection of the 5’UTR conformers BMH and LDI, the dimerization mix contained 0.1 µmol of 5’UTR 
and 6 µmol of DIS decoy, and the reactions were resolved in 4% native polyacrylamide gels in 0.25X 
TBE using 0.25X TBE as the running buffer. 
3.4. HIV-1 ex vivo inhibition assays 
For these assays 250,000 HEK293T cells per well were plated in a 24-well plate using 500 µL/well 
of DMEM, 10% fetal bovine serum (FBS) and L-glutamine 2 mM the day before transfection. Then,  
1 µL of Lipofectamine 2000 reagent (Invitrogen, CA, USA) was mixed with 25 µL of Opti-MEM® 
(PAA Laboratories GmbH, Austria) and incubated for 5 min at room temperature. Following this,  
100 ng of pNL4.3 were mixed with either 300 ng of a pU6 DNA plasmid construct coding for a 
specific RNA inhibitor or 500 ng of a pre-synthesized inhibitory RNA in 25 µL of Opti-MEM®, and 
incubated for 5 min. Lipofectamine and nucleic acid solutions were mixed and incubated at room 
temperature for 20 min. Then, 450 µL of DMEM, 10% FBS and 2 mM L-glutamine were added. The 
supernatant was carefully removed from each well by aspiration and 500 µL transfecting-mix was 
added. Two days after transfection, the supernatants were removed and processed using the Genscreen 
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HIV-1 Ag assay (BioRad, CA, USA) for viral protein p24 antigen quantification, following the 
manufacturer’s instructions. The DNA for transfection was prepared using the Plasmid Mini Kit 
(Quiagen, The Netherlands), following manufacturer’s instructions. Each treatment was assayed in 
triplicate and statistical analysis was performed by Kruskal-Wallis non-parametric test followed by 
multiple Dunnet comparison tests to check differences against the control. 
3.5. Detection of interferon-response activation by semi-quantitative RT-PCR 
Total RNA was extracted from the cells by the Trizol® reagent (Invitrogen), following 
manufacturer’s recommendations but adding an extra incubation of the aqueous phase after chloroform 
extraction with 1 U of RQ1DNase (Promega, WI, USA) at 37 ºC for 15 min to prevent genomic DNA 
contamination. This was followed by an additional chloroform extraction. Reverse transcription was 
performed using the Reverse-Transcriptor kit (Roche), where 100 ng of total RNA was incubated at  
37 ºC for 20 min with 0.5 U of RQ1 DNase (Promega) and 20 U of the RNase inhibitor (Promega). 
The RNA was incubated at 65 ºC for 10 min, then the temperature was brought down quickly to 4 ºC 
and 3.2 µg of random hexamer primers were added. The reaction mixes contained 1 mM dNTPs and 
10 U of reverse transcriptase (RT) in reaction buffer in a final volume of 20 µL. Annealing was 
performed at 25 ºC for 10 min and the reactions were run at 60 ºC for one hour. Finally, the RT was 
inactivated at 85 ºC for 5 min. Semi-quantitative PCR was performed by the Reddy Mix PCR Master 
Mix (Thermo Scientific). The reactions were performed in a total volume of 10 µL containing 2.5 µL 
of cDNA, 3 pmol of each GAPDH-specific primer and 10 pmol of ISG56-specific primers.  
4. Conclusions 
Nowadays, there are multiple RNA-based approaches with the therapeutic potential to interfere with 
viral functions. Functional RNA moieties have been involved in many regulatory processes. 
Understanding these functionalities, like RNA catalysis or HIV genomic RNA dimerization, may 
enable the design of therapeutic RNAs. Here we have proven that the combination of functional 
inhibitor RNA moieties directed against different HIV-1 5’UTR RNA targets in a single chimeric 
molecule results in bi-functional RNA molecules that fully conserve both inhibitory activities. Both 
hammerhead and hairpin ribozyme domains were explored as 5’UTR RNA trans-cleaving elements 
targeting two available cleavage sites surrounding the +113 and +159 positions. The DIS domain 
within the 5’UTR RNA, responsible for triggering the HIV-1 RNA dimerization, was used as target for 
a decoy and an antisense RNA. 
The ex vivo HIV-1 inhibition assays demonstrated up to 90% effect measured as viral protein p24 
levels in the supernatant of cells transfected with the HIV pro-viral DNA in a post-integrative model 
system. Inhibitory chimera RNAs achieved a complete in vitro inhibition of the essential viral 
dimerization process. A model of the implication of both 5’UTR folding isoforms LDI and BMH in the 
dimerization process is proposed. The results summarized here indicate that in the absence of ionic 
strength, the 5’UTR folds in vitro into the BMH monomeric conformer, which is competent for 
dimerization. This conformer quickly switches to the LDI form after the addition of ions. Under these 
conditions, a low proportion of folded BMH molecules can dimerize into a stable complex, ensuring 
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the existence of enough HIV genome dimers for packaging and the generation of infective  
viral particles. 
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